Center for Scientific Review; Notice of Closed Meetings, 25455-25456 [2020-09307]
Download as PDF
<![CDATA[
Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices
widespread health risks posed by
COVID–19 to the American public. The
public meeting will now be a one-day
webinar and conference call held only
on Tuesday, June 16, 2020, from 9:30
a.m.–1:30 p.m. Eastern Time. The
webinar link, conference dial-in
number, meeting materials, and updates
will be available on the NACNHSC
website: https://nhsc.hrsa.gov/about/
national-advisory-council-nhsc/
index.html.
FOR FURTHER INFORMATION CONTACT:
Diane Fabiyi-King, Designated Federal
Official, Division of the National Health
Service Corps, HRSA. Address: 5600
Fishers Lane, Room 14N110, Rockville,
Maryland 20857; phone (301) 443–3609;
or DFabiyi-King@hrsa.gov.
Correction: This meeting will be a
one-day webinar and conference call
only, rather than an in-person, two-day
meeting as previously announced in the
Federal Register, Vol. 84, No. 244 on
Thursday, December 19, 2019 (FR Doc.
2019–27357 Filed 12–18–19).
Maria G. Button,
Director, Executive Secretariat.
[FR Doc. 2020–09264 Filed 4–30–20; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Special Emphasis
Panel Genomic Resource SEP.
Date: June 9, 2020.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700
B Rockledge Drive, Room 3189 Bethesda, MD
20892 (Telephone Conference Call).
VerDate Sep<11>2014
08:07 May 01, 2020
Jkt 250001
Contact Person: Keith McKenney, Ph.D.
Scientific Review Officer National Human
Genome Research Institute National
Institutes of Health 6700 B Rockledge Drive,
Room 3189 Bethesda, MD 20892 301–594–
4280 mckenneyk@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: April 27, 2020.
Melanie Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–09309 Filed 4–30–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Human Genome Research
Institute; Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Human
Genome Research Institute Initial Review
Group; Genome Research Review Committee.
Date: June 4, 2020.
Time: 11:00 a.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Human Genome Research
Institute, National Institutes of Health, 6700B
Rockledge Drive, Room 3189, Bethesda, MD
20892 (Telephone Conference Call).
Contact Person: Keith McKenney, Ph.D.,
Scientific Review Officer, National Human
Genome Research Institute, National
Institutes of Health, 6700B Rockledge Drive,
Room 3189, Bethesda, MD 20892, 301–594–
4280, mckenneyk@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.172, Human Genome
Research, National Institutes of Health, HHS)
Dated: April 27, 2020.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–09308 Filed 4–30–20; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00073
Fmt 4703
Sfmt 4703
25455
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Cardiovascular and
Respiratory Sciences Integrated Review
Group; Lung Cellular, Molecular, and
Immunobiology Study Section.
Date: June 2–3, 2020.
Time: 9:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Dr., Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: George M Barnas, Ph.D.,
Scientific Review Officer Center for Scientific
Review, National Institutes of Health, 6701
Rockledge Drive, Room 2180, MSC 7818,
Bethesda, MD 20892, 301–435–0696,
barnasg@csr.nih.gov.
Name of Committee: Digestive, Kidney and
Urological Systems Integrated Review Group;
Kidney Molecular Biology and Genitourinary
Organ Development.
Date: June 4, 2020.
Time: 8:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Dr., Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Ganesan Ramesh, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2182,
MSC 7818 Bethesda, MD 20892, 301–827–
5467, ganesan.ramesh@nih.gov.
Name of Committee: Oncology 1-Basic
Translational Integrated Review Group;
Tumor Cell Biology Study Section.
Date: June 4–5, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II 6701, Rockledge Dr., Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Charles Morrow, MD,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6202,
E:\FR\FM\01MYN1.SGM
01MYN1
25456
Federal Register / Vol. 85, No. 85 / Friday, May 1, 2020 / Notices
MSC 7804, Bethesda, MD 20892, 301–408–
9850, morrowcs@csr.nih.gov.
Name of Committee: Infectious Diseases
and Microbiology Integrated Review Group;
Bacterial Pathogenesis Study Section.
Date: June 4–5, 2020.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Dr., Bethesda,
MD 20892 (Virtual Meeting).
Contact Person: Marci Scidmore, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3192,
MSC 7808, Bethesda, MD 20892 301–435–
1149 marci.scidmore@nih.gov,
Name of Committee: Cell Biology
Integrated Review Group; Development—1
Study Section.
Date: June 4, 2020.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Thomas Beres, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5148,
MSC 7840 Bethesda, MD 20892, 301–435–
1175, berestm@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: April 27, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–09307 Filed 4–30–20; 8:45 am]
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Allergy and Infectious Diseases Special
Emphasis Panel NIAID Omnibus BAA 2020–
1: Research Area 003—Advanced
Development of Vaccine Candidates for
Biodefense and Emerging Infectious Diseases.
Date: May 11, 2020.
Time: 9:30 a.m. to 3:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G41B,
Rockville, MD 20892 (Telephone Conference
Call).
Contact Person: Zhuqing (Charlie) Li,
Ph.D., Scientific Review Officer, Scientific
Review Program, Division of Extramural
Activities, National Institute of Allergy and
Infectious Diseases, National Institutes of
Health, 5601 Fishers Lane, Room 3G41B,
Bethesda, MD 20892–9823, (240) 669–5068,
zhuqing.li@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.855, Allergy, Immunology,
and Transplantation Research; 93.856,
Microbiology and Infectious Diseases
Research, National Institutes of Health, HHS)
Dated: April 27, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2020–09310 Filed 4–30–20; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
Substance Abuse and Mental Health
Services Administration
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine and Oral
Fluid Drug Testing for Federal
Agencies
National Institutes of Health
National Institute of Allergy and
Infectious Diseases; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
VerDate Sep<11>2014
08:07 May 01, 2020
Jkt 250001
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITFs) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs using Urine or Oral Fluid
(Mandatory Guidelines).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
SUMMARY:
PO 00000
Frm 00074
Fmt 4703
Sfmt 4703
any laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
internet at https://www.samhsa.gov/
workplace/resources/drug-testing/
certified-lab-list.
FOR FURTHER INFORMATION CONTACT:
Anastasia Donovan, Division of
Workplace Programs, SAMHSA/CSAP,
5600 Fishers Lane, Room 16N06B,
Rockville, Maryland 20857; 240–276–
2600 (voice); Anastasia.Donovan@
samhsa.hhs.gov (email).
SUPPLEMENTARY INFORMATION: The
Department of Health and Human
Services (HHS) notifies federal agencies
of the laboratories and Instrumented
Initial Testing Facilities (IITFs)
currently certified to meet the standards
of the Mandatory Guidelines for Federal
Workplace Drug Testing Programs
(Mandatory Guidelines) using Urine and
of the laboratories currently certified to
meet the standards of the Mandatory
Guidelines using Oral Fluid.
The Mandatory Guidelines using
Urine were first published in the
Federal Register on April 11, 1988 (53
FR 11970), and subsequently revised in
the Federal Register on June 9, 1994 (59
FR 29908); September 30, 1997 (62 FR
51118); April 13, 2004 (69 FR 19644);
November 25, 2008 (73 FR 71858);
December 10, 2008 (73 FR 75122); April
30, 2010 (75 FR 22809); and on January
23, 2017 (82 FR 7920).
The Mandatory Guidelines using Oral
Fluid were first published in the
Federal Register on October 25, 2019
(84 FR 57554) with an effective date of
January 1, 2020.
The Mandatory Guidelines were
initially developed in accordance with
Executive Order 12564 and section 503
of Public Law 100–71 and allowed urine
drug testing only. The Mandatory
Guidelines using Urine have since been
revised, and new Mandatory Guidelines
allowing for oral fluid drug testing have
been published. The Mandatory
Guidelines require strict standards that
laboratories and IITFs must meet in
order to conduct drug and specimen
validity tests on specimens for federal
agencies. HHS does not allow IITFs for
oral fluid testing.
To become certified, an applicant
laboratory or IITF must undergo three
E:\FR\FM\01MYN1.SGM
01MYN1
]]>Agencies
[Federal Register Volume 85, Number 85 (Friday, May 1, 2020)]
[Notices]
[Pages 25455-25456]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-09307]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Cardiovascular and Respiratory Sciences
Integrated Review Group; Lung Cellular, Molecular, and Immunobiology
Study Section.
Date: June 2-3, 2020.
Time: 9:00 a.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Dr., Bethesda, MD 20892 (Virtual Meeting).
Contact Person: George M Barnas, Ph.D., Scientific Review
Officer Center for Scientific Review, National Institutes of Health,
6701 Rockledge Drive, Room 2180, MSC 7818, Bethesda, MD 20892, 301-
435-0696, [email protected].
Name of Committee: Digestive, Kidney and Urological Systems
Integrated Review Group; Kidney Molecular Biology and Genitourinary
Organ Development.
Date: June 4, 2020.
Time: 8:00 a.m. to 6:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Dr., Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Ganesan Ramesh, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2182, MSC 7818 Bethesda, MD
20892, 301-827-5467, [email protected].
Name of Committee: Oncology 1-Basic Translational Integrated
Review Group; Tumor Cell Biology Study Section.
Date: June 4-5, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II 6701,
Rockledge Dr., Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Charles Morrow, MD, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6202,
[[Page 25456]]
MSC 7804, Bethesda, MD 20892, 301-408-9850, [email protected].
Name of Committee: Infectious Diseases and Microbiology
Integrated Review Group; Bacterial Pathogenesis Study Section.
Date: June 4-5, 2020.
Time: 9:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Dr., Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Marci Scidmore, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3192, MSC 7808, Bethesda, MD
20892 301-435-1149 [email protected],
Name of Committee: Cell Biology Integrated Review Group;
Development--1 Study Section.
Date: June 4, 2020.
Time: 9:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Rockledge II, 6701
Rockledge Drive, Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Thomas Beres, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 5148, MSC 7840 Bethesda, MD 20892, 301-435-
1175, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: April 27, 2020.
Tyeshia M. Roberson,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2020-09307 Filed 4-30-20; 8:45 am]
BILLING CODE 4140-01-P
